Preda A, Carbone F, Tirandi A, Montecucco F, Liberale L. Obesity phenotypes and cardiovascular risk: from pathophysiology to clinical management. Rev Endocr Metab Disord. 2023;24:901–19.
Article PubMed PubMed Central Google Scholar
Kachur S, Lavie CJ, de Schutter A, Milani RV, Ventura HO. Obesity and cardiovascular diseases. Minerva Med. 2017;108(3):212–28. https://doi.org/10.23736/S0026-4806.17.05022-4
Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol-Cell Physiol. 2021;320:C375–91.
Calabrò P, Yeh E. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. SubCell Biochem. 2007;42:62–91.
Liu Z, Wu KKL, Jiang X, Xu A, Cheng KKY. The role of adipose tissue senescence in obesity- and ageing-related metabolic disorders. Clin Sci. 2020;134:315–30.
Pang J, Nguyen VT, Rhodes DH, Sullivan ME, Braunschweig C, Fantuzzi G. Relationship of galectin-3 with obesity, IL-6, and CRP in women. J Endocrinol Invest. 2016;39:1435–43.
Zhang Y, Lv P, Li Y, Zhang Y, Cheng C, Hao H, et al. Inflammatory cytokine interleukin-6 (IL-6) promotes the proangiogenicability of adipose stem cells from obese subjects via the IL-6 signaling pathway. Curr Stem Cell Res Ther. 2023;18:93–104.
Al Madhoun A, Kochumon S, Haddad D, Thomas R, Nizam R, Miranda L, et al. Adipose tissue caveolin-1 upregulation in obesity involves TNF-α/NF-κB mediated signaling. Cells. 2023;12:1019.
Article PubMed PubMed Central Google Scholar
Fitzgibbons TP, Czech MP. Emerging evidence for beneficial macrophage functions in atherosclerosis and obesity-induced insulin resistance. J Mol Med. 2016;94:267–75.
Sudhakar M, Silambanan S, Chandran AS, Prabhakaran AA, Ramakrishnan R. C-reactive protein (CRP) and leptin receptor in obesity: binding of monomeric CRP to leptin receptor. Front Immunol. 2018;9:1167.
Article PubMed PubMed Central Google Scholar
Zhu C, Huang D, Ma H, Qian C, You H, Bu L, et al. High-sensitive CRP correlates with the severity of liver steatosis and fibrosis in obese patients with metabolic dysfunction associated fatty liver disease. Front Endocrinol. 2022;13:848937.
Pardina E, Ferrer R, Baena-Fustegueras JA, Rivero J, Lecube A, Fort JM, et al. Only C-reactive protein, but not TNF-α or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg. 2012;22:131–9.
Yatsuya H, Jeffery RW, Langer SL, Mitchell N, Flood AP, Welsh EM, et al. Changes in C-reactive protein during weight loss and the association with changes in anthropometric variables in men and women: LIFE Study. Int J Obes. 2011;35:684–91.
Jaliliyan A, Madankan A, Mosavari H, Khalili P, Pouraskari B, Lotfi S, et al. The impact of metabolic and bariatric surgery on Apo B100 levels in individuals with high BMI: a multi-centric prospective cohort study. Obes Surg [Internet]. 2024 [cited 2024 Jun 6]; Available from: https://link.springer.com/10.1007/s11695-024-07258-6
Cottam A, Cottam D, Roslin M, Surve A. Exploring bariatric surgery’s impact on weight loss and diabetes: sodium and glucose receptor modulation. JSLS J Soc Laparosc Robot Surg. 2024;28:e2023.00051.
Pakiet A, Haliński ŁP, Rostkowska O, Kaska Ł, Proczko-Stepaniak M, Śledziński T, et al. The effects of one-anastomosis gastric bypass on fatty acids in the serum of patients with morbid obesity. Obes Surg. 2021;31:4264–71.
Article PubMed PubMed Central Google Scholar
Kermansaravi M, Shahmiri SS, Khalaj A, Jalali SM, Amini M, Alamdari NM, et al. The first web-based Iranian National Obesity and Metabolic Surgery Database (INOSD). Obes Surg. 2022;32:2083–6.
Salminen P, Kow L, Aminian A, Kaplan LM, Nimeri A, Prager G, et al. IFSO consensus on definitions and clinical practice guidelines for obesity management—an international Delphi study. Obes Surg. 2024;34:30–42.
Kermansaravi M, Kabir A, Mousavimaleki A, Pazouki A. Association between hiatal hernia and gastroesophageal reflux symptoms after one-anastomosis/mini gastric bypass. Surg Obes Relat Dis. 2020;16:863–7.
Huang J, Chen Y, Wang X, Wang C, Yang J, Guan B. Change in adipokines and gastrointestinal hormones after bariatric surgery: a meta-analysis. Obes Surg. 2023;33:789–806.
Chang Y-C, Hsu C-N, Chong K, Yang P-J, Ser K-H, Lee P-C, et al. Roux-en-Y and one-anastomosis gastric bypass surgery are superior to sleeve gastrectomy in lowering glucose and cholesterol levels independent of weight loss: a propensity-score weighting analysis. Obes Surg. 2023;33:3035–50.
Salman MA, Abdallah A, Mikhail HMS, Abdelsalam A, Ibrahim AH, Sultan AAEA, et al. Long-term impact of mini-gastric bypass on inflammatory cytokines in cohort of morbidly obese patients: a prospective study. Obes Surg. 2020;30:2338–44.
Yang P-J, Lee W-J, Tseng P-H, Lee P-H, Lin M-T, Yang W-S. Bariatric surgery decreased the serum level of an endotoxin-associated marker: lipopolysaccharide-binding protein. Surg Obes Relat Dis. 2014;10:1182–7.
Liou J-M, Lin J-T, Lee W-J, Wang H-P, Lee Y-C, Chiu H-M, et al. The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery. Obes Surg. 2008;18:84–9.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
Kumar PA, Jha SK, Prasad A, Jindal N, Bhandari S. To study high-sensitivity CRP levels in overweight and obese individuals. J Adv Med Med Res. 2023;35:29–34.
Zhang C, Zhang J, Liu Z, Zhou Z. More than an anti-diabetic bariatric surgery, metabolic surgery alleviates systemic and local inflammation in obesity. Obes Surg. 2018;28:3658–68.
Xu G, Song M. Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery. Surg Obes Relat Dis. 2021;17:231–8.
Van Veldhuisen SL, Gorter TM, Van Woerden G, De Boer RA, Rienstra M, Hazebroek EJ, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43:1955–69.
Article PubMed PubMed Central Google Scholar
Biobaku F, Ghanim H, Monte SV, Caruana JA, Dandona P. Bariatric surgery: remission of inflammation, cardiometabolic benefits, and common adverse effects. J Endocr Soc. 2020;4:bvaa049.
Article PubMed PubMed Central Google Scholar
Lautenbach A, Stoll F, Mann O, Busch P, Huber TB, Kielstein H, et al. Long-term improvement of chronic low-grade inflammation after bariatric surgery. Obes Surg. 2021;31:2913–20.
Article PubMed PubMed Central Google Scholar
Hinerman AS, Barinas-Mitchell EJM, El Khoudary SR, Courcoulas AP, Wahed AS, King WC. Change in C-reactive protein after Roux-en-Y gastric bypass through 7 years of follow-up. Surg Obes Relat Dis. 2022;18:902–10.
Article PubMed PubMed Central Google Scholar
Santos AL, Silva SAD, Cavalcante-E-Silva LM, Leão LHDA, Coutinho LR, Oliveira FDSC, et al. Weight regain and the metabolic profile of women in the postoperative period of bariatric surgery: a multivariate analysis. ABCD Arq Bras Cir Dig São Paulo. 2023;36:e1755.
Plamper A, Lingohr P, Nadal J, Trebicka J, Brol MJ, Woestemeier A, et al. A long-term comparative study between one anastomosis gastric bypass and sleeve gastrectomy. J Gastrointest Surg. 2023;27:47–55.
Askarpour M, Khani D, Sheikhi A, Ghaedi E, Alizadeh S. Effect of bariatric surgery on serum inflammatory factors of obese patients: a systematic review and meta-analysis. Obes Surg. 2019;29:2631–47.
Robert M, Poghosyan T, Maucort-Boulch D, Filippello A, Caiazzo R, Sterkers A, et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study. Lancet Diabetes Endocrinol. 2024;12:267–76.
留言 (0)